EUVIMEDEUVIMED entdecken
Open Access

Emollients to Prevent Pediatric Eczema

Eric L Simpson, LeAnn C Michaels, Katrina Ramsey, Lyle J Fagnan, Donald E Nease, Mary Henningfield, Rowena J Dolor, Jodi Lapidus, Xaviera Martinez-Ziegenfuss, Annette Vu, Laura Ferrara, Katharine E Zuckerman und 3 weitere

JAMA Dermatology · 01.09.2025 · 161 (9) · 957

DOI: 10.1001/jamadermatol.2025.2357 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Dermatology, erschienen am 01.09.2025. Verfasst von Eric L Simpson und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Oregon Health & Science University, Portland. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, NCATS NIH HHS.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Atopic dermatitis (AD) imposes a global health burden for children and is a risk factor for developing food allergy and asthma. Few studies have evaluated emollient intervention for primary AD prevention in infants not selected for risk.

Objective

To determine whether emollient intervention in infants not selected for risk reduces AD incidence by age 24 months. Design, Setting, and Participants A randomized, decentralized pragmatic clinical trial was conducted that involving 1247 infant-parent dyads recruited from 25 community-based pediatric and family medicine clinics that are members of 4 statewide practice-based research networks. Participants were recruited from July 2018 to February 2021, with follow-up completed through February 2023.

Intervention

Dyads were randomized to 1 of 2 groups: a daily full-body emollient application daily moisturizer group starting by age 9 weeks or a control group that refrained from emollient use. Main Outcomes and Measures The primary outcome was physician-diagnosed AD recorded in the patient’s medical record by age 24 months. Participants completed quarterly electronic surveys to report adverse events and alert the team if an AD diagnosis had been made. Trained research coordinators abstracted participants’ medical records.

Results

Of 1247 infants, 553 (44.3%) were female, and the mean (SD) age at randomization was 23.9 (16.3) days. At 24 months, the cumulative incidence of AD was 36.1% (SE, 2.1) in the daily moisturizer group and 43.0% (SE 2.1) in the control group, with a relative risk (RR) of 0.84 (95% CI, 0.73-0.97; P = .02), and the magnitude of effect was larger in the population not at high risk of AD (RR, 0.75; 95% CI, 0.60-0.90; P = .01). The protective effect was significantly modified by the presence of a dog in the home (RR, 0.68; 95% CI, 0.50-0.90; P = .01). There were no between-group differences in cutaneous adverse events. Conclusions and Relevance This randomized clinical trial found that daily emollient application beginning before age 9 weeks in a representative US population not selected for risk reduced the cumulative incidence of AD at age 24 months. Implementing this approach to pediatric skin care may be a feasible way to reduce the burden of AD in US communities. Trial Registration ClinicalTrials.gov Identifier: NCT03409367

Autor:innen und Institutionen

  • Department of Dermatology, Oregon Health & Science University, Portland.
  • Division of Informatics, Clinical Epidemiology and Translational Data Science, Oregon Health & Science University, Portland.
  • School of Public Health, Portland State University/Oregon Health & Science University, Portland.
  • Oregon Rural Practice Based Research Network, Oregon Health & Science University, Portland.
  • Department of Family Medicine, University of Colorado School of Medicine, Boulder.
  • Wisconsin Research and Education Network, Department of Family Medicine and Community Health, University of Wisconsin-Madison.

Förderung

  • NIAMS NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Simpson, E. L., Michaels, L. C., Ramsey, K., Fagnan, L. J., Nease, D. E., Henningfield, M., Dolor, R. J., Lapidus, J., Martinez-Ziegenfuss, X., Vu, A., Ferrara, L., Zuckerman, K. E., Morris, C. D., Williams, H. C., & CASCADE Consortium (2025). Emollients to Prevent Pediatric Eczema. JAMA Dermatology, 161(9), 957. https://doi.org/10.1001/jamadermatol.2025.2357

Vancouver

Simpson EL, Michaels LC, Ramsey K, Fagnan LJ, Nease DE, Henningfield M, et al. Emollients to Prevent Pediatric Eczema. JAMA Dermatology. 2025;161(9):957. doi:10.1001/jamadermatol.2025.2357

BibTeX
@article{Simpson2025,
  author = {Simpson, Eric L and Michaels, LeAnn C and Ramsey, Katrina and Fagnan, Lyle J and Nease, Donald E and Henningfield, Mary and Dolor, Rowena J and Lapidus, Jodi and Martinez-Ziegenfuss, Xaviera and Vu, Annette and Ferrara, Laura and Zuckerman, Katharine E and Morris, Cynthia D and Williams, Hywel C and CASCADE Consortium, CASCADE Consortium},
  title = {Emollients to Prevent Pediatric Eczema},
  journal = {JAMA Dermatology},
  year = {2025},
  volume = {161},
  number = {9},
  pages = {957},
  doi = {10.1001/jamadermatol.2025.2357}
}
Kostenlos starten →